loading page

Solute carrier family 47 member 1 gene polymorphism detection improves the therapeutic effect of diabetes.
  • Jing Song,
  • Jiajie Luan
Jiajie Luan

Corresponding Author:[email protected]

Author Profile

Abstract

Abstract: Purpose: To explore the impact of SLC47A1 ( Solute carrier family 47 member 1, SLC47A1 ) gene polymorphism on the treatment of diabetes, we conducted a statistical analysis of the SLC47A1 genetic testing results and patient data in the second quarter of 2019 in our hospital. Methods: We investigated 372 cases of SLC47A1 gene test reports and patient medical records, collected information on gender, age, diabetes type, complications and the relationship between genotype and biochemical indicators before and after metformin treatment to explore the guiding effect of SLC47A1 gene test on metformin. Results: GG genotype had the highest incidence in men, <30 years or type 2 diabetes patients; GA genotypes have the highest incidence in women, >30 years or type 2 diabetes patients; and AA genotype have the highest incidence in men, <30 years or type 1 diabetes. Besides, the complications that each genotype tended to occur were also significantly different. At the same time, compared with the biochemical parameters before the guidance, the biochemical parameters after the guidance were significantly improved. In addition, in all genotypes patients, only patients with AA genotype had the best improvement in biochemical parameters, Among them, the HbA1b parameters of the GG genotype patients were significantly reduced; the 2h-CP, HbA1b and HbA1c parameters of the GA genotype patients were significantly reduced; and also the Glu, 2h -CP, HbA1b and HbA1c parameters of AA genotype patients were all significantly reduced. Conclusion: The guidance of SLC47A1 gene polymorphism on metformin medication could improve diabetes treatment effect, and patients with AA genotype had the best treatment effect.